Kookjeon Pharmaceutical Co., Ltd. (KOSDAQ:307750)
South Korea · Delayed Price · Currency is KRW 1,957.00
-78.00 (-3.83%)
At close: Jul 28, 2026
Kookjeon Pharmaceutical Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 105,651 | 168,844 | 172,478 | 306,192 | 324,839 | 537,308 | |
Market Cap Growth | -50.31% | -2.11% | -43.67% | -5.74% | -39.54% | - |
Enterprise Value | 116,687 | 189,611 | 178,557 | 319,290 | 284,635 | - |
Last Close Price | 1957.00 | 3365.00 | 3515.00 | 6222.17 | 6590.26 | 10900.81 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 99.34 | 63.47 | 36.30 | 133.06 |
PS Ratio | 0.83 | 1.29 | 1.26 | 2.51 | 3.13 | 6.30 |
PB Ratio | 0.98 | 1.76 | 1.77 | 3.14 | 3.52 | 6.46 |
P/TBV Ratio | 1.00 | 1.78 | 1.80 | 3.22 | 3.60 | 6.50 |
P/FCF Ratio | 23.34 | 22.53 | 82.14 | - | - | - |
P/OCF Ratio | 12.51 | 15.92 | 17.31 | - | - | 176.63 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.92 | 1.45 | 1.31 | 2.62 | 2.75 | - |
EV/EBITDA Ratio | 22.35 | 71.19 | 32.63 | 33.11 | 57.72 | - |
EV/EBIT Ratio | - | - | 486.92 | 49.05 | 81.60 | - |
EV/FCF Ratio | 25.78 | 25.30 | 85.04 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.37 | 0.48 | 0.67 | 0.81 | 0.64 | 0.09 |
Debt / EBITDA Ratio | 7.68 | 17.23 | 11.94 | 8.17 | 12.03 | 1.09 |
Debt / FCF Ratio | 8.88 | 6.13 | 31.11 | - | - | - |
Net Debt / Equity Ratio | 0.09 | 0.16 | 0.19 | 0.14 | -0.39 | -0.38 |
Net Debt / EBITDA Ratio | 1.87 | 5.77 | 3.38 | 1.45 | -7.22 | -4.35 |
Net Debt / FCF Ratio | 2.17 | 2.05 | 8.81 | -0.31 | 1.22 | 4.26 |
Asset Turnover | 0.64 | 0.67 | 0.62 | 0.58 | 0.68 | - |
Inventory Turnover | 4.40 | 5.02 | 4.22 | 4.05 | 4.62 | - |
Quick Ratio | 0.91 | 0.82 | 0.85 | 0.94 | 1.67 | 2.72 |
Current Ratio | 1.32 | 1.13 | 1.19 | 1.24 | 2.02 | 3.52 |
Return on Equity (ROE) | -7.91% | -4.98% | 0.55% | 4.95% | 10.12% | - |
Return on Assets (ROA) | -0.00% | -0.82% | 0.10% | 1.93% | 1.44% | - |
Return on Invested Capital (ROIC) | -0.01% | -2.26% | 0.20% | 7.75% | 5.15% | 9.38% |
Return on Capital Employed (ROCE) | 0.00% | -2.30% | 0.30% | 5.20% | 2.80% | 7.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -7.43% | -2.55% | 1.01% | 1.58% | 2.76% | 0.75% |
FCF Yield | 4.28% | 4.44% | 1.22% | -14.46% | -9.02% | -1.37% |
Payout Ratio | - | - | 28.26% | - | 5.48% | - |
Buyback Yield / Dilution | -1.15% | -0.51% | -1.09% | 4.23% | -16.16% | - |